What Happened?

Shares of medical device company Zimmer Biomet (NYSE:ZBH) fell 10.2% in the afternoon session after the company reported underwhelming first quarter 2025 results as it lowered its full-year EPS guidance. A key takeaway was the weak growth. Sales were up just 1% as demand for some product lines came in weaker. While hips and trauma gear did well, others, like bone cement and surgical tools, dropped nearly 5%. Overall, this was a softer quarter.

The shares closed the day at $90.48, down 11.6% from previous close.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Zimmer Biomet? Access our full analysis report here, it’s free .

What The Market Is Telling Us

Zimmer Biomet’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. Moves this big are rare for Zimmer Biomet and indicate this news significantly impacted the market’s perception of the business.

Zimmer Biomet is down 13.4% since the beginning of the year, and at $90.48 per share, it is trading 25.5% below its 52-week high of $121.44 from May 2024. Investors who bought $1,000 worth of Zimmer Biomet’s shares 5 years ago would now be looking at an investment worth $766.65.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link .